New menopause treatment approved for NHS use in Scotland

A new treatment for menopause symptoms for women who cannot take HRT has been approved for use by the NHS in Scotland.

The Scottish Medicines Consortium has recommended that women can now be prescribed fezolinetant, also known as Veoza, to help with symptoms such as hot flushes and night sweats.

While these symptoms can be severe and long-lasting, there have been limited options for treatment for women who are unable to take hormone replacement therapy (HRT).

However, the new drug works by selectively blocking a neurotransmitter in the brain that is involved in causing hot flushes, with clinical trials showing it can reduce both the frequency and the severity of hot flushes and night sweats.

About 400,000 women in Scotland are said to be of menopausal age, with the drug manufacturer Astellas Pharma Ltd saying up to 48,000 of those could benefit from the new treatment.

Announcing the decision, SMC chair Dr Rob Peel, said: “We know that menopausal hot flushes and night sweats can substantially affect quality of life.

“For those who cannot take HRT, effective treatment options are limited. Fezolinetant provides a non-hormonal treatment option, and we know our decision will be welcomed.”

Dr Timir Patel, medical director of Astellas UK, said the firm was “pleased that this important additional treatment option will be available to women in Scotland, helping to support more personalised care for those experiencing hot flushes and night sweats”.

Dr Kay McAllister, consultant gynaecologist and clinical lead for menopause services at NHS Glasgow and Greater Clyde, meanwhile, said: “Today’s decision marks a positive development for the wellbeing of Scottish women.

“In clinical practice, I see how hot flushes and night sweats impact sleep and overall quality of life in my patients.

“The availability of this targeted treatment offers a welcome choice and further options for patients.”